1. UNCOVER-1 study group; UNCOVER-2 study group; UNCOVER-3 study group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis;Gordon;N Engl J Med,2016
2. Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes;Kushner;Womens Health (Lond),2016
3. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies;Nyirjesy;Curr Med Res Opin,2014
4. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections,2015
5. Severe candidal balanoposthitis on concurrent treatment with secukinumab and the antidiabetic agent empagliflozin (sodium-glucose cotransporter 2 inhibitor - SGLT2-inhibitor);Moldenhauer;J Dtsch Dermatol Ges,2019